ProPhase Labs, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ProPhase Labs, Inc. - overview
Established
1989
Location
Doylestown, PA, US
Primary Industry
Pharmaceuticals
About
ProPhase Labs, Inc. is a biotechnology and genomics company dedicated to developing innovative health solutions and diagnostic tools to enhance patient care and promote early disease detection. Founded in 1989, ProPhase Labs, Inc. is headquartered in Doylestown, US.
The company specializes in biotechnology and genomics, focusing on health diagnostics. Ted Karkus serves as the CEO. There are no records of significant company pivots or subsidiary relationships. ProPhase Labs Inc.
specializes in next-generation biotechnology and genomics, focusing on innovative health solutions and diagnostic tools. Their core offerings include industry-leading Whole Genome Sequencing solutions designed to enhance genetic understanding and early diagnosis of various health conditions. Notably, the company has developed a potentially life-saving cancer test aimed at the early detection of esophageal cancer, alongside groundbreaking cancer therapeutics that utilize novel mechanisms of action. ProPhase Labs serves a diverse clientele that encompasses healthcare providers, research institutions, and consumers seeking advanced diagnostic capabilities.
Their products are marketed across multiple geographical regions including North America, Europe, and Asia, facilitating a wide reach in the healthcare sector. ProPhase Labs generates revenue through various business models, predominantly focusing on B2B and direct-to-consumer transactions. The company offers subscriptions for its genomic services, allowing healthcare facilities and researchers to access their Whole Genome Sequencing capabilities. Additionally, ProPhase Labs engages in partnerships with healthcare providers to distribute their diagnostic tests, such as the esophageal cancer test, efficiently within clinical settings.
Their flagship product, Cold-EEZE, has also contributed significantly to revenue through retail channels. The transaction structures are designed to facilitate streamlined sales processes, enhancing accessibility for end users in multiple sectors while reinforcing the company's commitment to innovation and growth in health and wellness solutions.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.prophaselabs.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
ProPhase Labs, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.